Equities research analysts predict that Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) will announce earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Deciphera Pharmaceuticals’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.67). Deciphera Pharmaceuticals reported earnings of ($0.66) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.5%. The company is expected to report its next earnings results on Tuesday, May 14th.
On average, analysts expect that Deciphera Pharmaceuticals will report full year earnings of ($2.97) per share for the current financial year, with EPS estimates ranging from ($3.21) to ($2.57). For the next year, analysts expect that the company will report earnings of ($3.20) per share, with EPS estimates ranging from ($3.28) to ($3.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13).
Several research firms recently commented on DCPH. BidaskClub cut shares of Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity cut their price objective on shares of Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday. Zacks Investment Research cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. B. Riley lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 1st. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Deciphera Pharmaceuticals in a research note on Thursday, December 20th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has an average rating of “Buy” and an average target price of $42.11.
In other news, insider Daniel Lee Flynn sold 152,629 shares of the business’s stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $26.00, for a total transaction of $3,968,354.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Thomas Patrick Kelly sold 5,000 shares of the business’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $25.18, for a total transaction of $125,900.00. The disclosure for this sale can be found here. Insiders sold a total of 198,426 shares of company stock worth $5,247,846 over the last quarter. Company insiders own 20.61% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Fosun International Ltd acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth about $4,958,000. Sphera Funds Management LTD. lifted its position in Deciphera Pharmaceuticals by 18.3% during the third quarter. Sphera Funds Management LTD. now owns 110,033 shares of the company’s stock valued at $4,260,000 after purchasing an additional 17,002 shares during the last quarter. Federated Investors Inc. PA bought a new stake in Deciphera Pharmaceuticals during the third quarter valued at approximately $1,113,000. Citadel Advisors LLC lifted its position in Deciphera Pharmaceuticals by 1,048.3% during the third quarter. Citadel Advisors LLC now owns 315,462 shares of the company’s stock valued at $12,215,000 after purchasing an additional 287,991 shares during the last quarter. Finally, Vanguard Group Inc lifted its position in Deciphera Pharmaceuticals by 2.1% during the third quarter. Vanguard Group Inc now owns 675,517 shares of the company’s stock valued at $26,156,000 after purchasing an additional 14,081 shares during the last quarter. Institutional investors own 57.28% of the company’s stock.
DCPH opened at $25.29 on Tuesday. The firm has a market capitalization of $952.45 million, a P/E ratio of -8.46 and a beta of 3.27. Deciphera Pharmaceuticals has a 12 month low of $18.55 and a 12 month high of $45.61. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.